It was a great pleasure to catch up with Susan Hutchinson (Orange County Migraine & Headache Center, Irvine, CA, USA) to discuss her recent study evaluating the safety and tolerability of rimegepant in adults with CV risk factors, for the prevention and treatment of migraine.
The abstract entitled: ‘Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What are the unmet needs in the treatment of migraine in adults with cardiovascular risk factors? (0:13)
- Could you give us a brief overview of the clinical development of small molecule CGRP receptor antagonists for migraine prevention and treatment? (1:01)
- Could you please describe your recent study evaluating the safety and tolerability of rimegepant in adults with CV risk factors? (1:40)
- What were the findings of this study and what are their implications for clinical practice? (3:32)
- What does the future migraine treatment landscape look like? (4:46)
Disclosures: In the past two years, Susan Hutchinson has served as a consultant/advisory board member for Alder/Lundbeck, Allergan/AbbVie, Amgen, Biohaven, Currax, electroCore, Impel, Lilly, Novartis, Teva, Theranica, Upsher-Smith; and is on the speaker’s bureau for AbbVie, Amgen, Biohaven, electroCore, Lilly, Lundbeck, Novartis, Teva, Theranica and Upsher-Smith.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Robert Music, The Migraine Trust: Improving migraine care – ensuring patient-focussed diagnosis and treatment in the UK
“Migraine is a common and complex brain disorder that affects 10 million people in the UK, impacting their ability to work, relationships and mental health. It’s poorly understood by the public and even many health professionals, and there are challenges around diagnosis, care and access to the right treatment. ” – Rob Music, CEO, The […]
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!